Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
HOME > COLUMN
COLUMN
-
3 Reasons Why KOL Management Is No Longer Enough
October 22, 2014
-
Successful People Have the Best Information
September 24, 2014
-
Is Your Body Language Louder than Your Speech?
August 25, 2014
-
Taking Pride in Small Things Makes Big Things Possible
July 25, 2014
-
It’s Moments Like These
June 27, 2014
-
How to Hire a Medical Doctor Who Is a Business Person First
May 23, 2014
-
Transforming from a Key Opinion Leader to a Key Account
April 25, 2014
-
Emerging Immunotherapy of Cancer: 2
April 11, 2014
-
Emerging Immunotherapy of Cancer: 1
April 10, 2014
-
Sun Tzu and the Art of Interviewing
March 18, 2014
-
2014: Year of the (Trojan) Horse – CROs Are about to Take the Pharma Industry by Storm
February 21, 2014
-
The Time Is Now for Medical Affairs
January 17, 2014
-
Blue Ocean Recruiting
December 20, 2013
-
Recruitment: Save Yourself from the Insanity of Diminished Returns
November 22, 2013
-
Current Topics in the Pharmaceutical Industry: Emerging Therapeutics with New Modes of Action: 2
November 8, 2013
-
Current Topics in the Pharmaceutical Industry: Emerging Therapeutics with New Modes of Action: 1
November 7, 2013
-
A World of Opportunity for the Brave
November 1, 2013
-
Does HR Have an Image Problem?
September 20, 2013
-
Learn How to Give a Great Presentation and You May Break the “Gaijin Ceiling” to the Board Room at Headquarters
August 21, 2013
-
Watch out for the Gorilla when Hiring Talent
July 19, 2013
ページ
President Joe Biden enacted the Inflation Reduction Act (IRA) on August 16, 2022, significantly affecting Medicare prescription drug coverage and introducing targeted changes to Medicaid, the Children’s Health Insurance Program, and private health insurance. In January 2023, the Centers for…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…